GlassScriptPhysician profile
Lisa Dawn Spaulding
NPI 1255654158
$3,977.41
in general payments reported to CMS, 2019-2025
27 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $882 · 2023: $942 · 2024: $771 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.88 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $678.16 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $436.14 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $423.30 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $329.05 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $259.72 | 2022-2025 | |
| Amgen INC. | $248.93 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $246.18 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $209.33 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $136.26 | 2021-2025 | Eliquis, Camzyos |
| Abiomed | $130.41 | 2022-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $93.19 | 2023-2024 | Inpefa |
| Cvrx, INC. | $84.70 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $83.07 | 2025 | |
| Heartflow, INC. | $80.37 | 2022-2025 | Ffrct |
| Boston Scientific Corporation | $74.07 | 2022-2023 | Watchman Access System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.76 | 2022-2024 | Jardiance |
| Esperion Therapeutics, INC. | $60.38 | 2022-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $55.21 | 2022-2023 | |
| W. L. Gore & Associates, INC. | $53.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.20 | 2022-2023 | Xarelto |
| United Therapeutics Corporation | $46.68 | 2023 | Tyvaso, Orenitram |
| Edwards Lifesciences Corporation | $29.53 | 2025 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $29.10 | 2025 | Optimizer |
| Inari Medical, INC. | $23.43 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $19.93 | 2022 | |
| Glaxosmithkline, LLC. | $15.46 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $14.63 | 2025 | Aveir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Spaulding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.